{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:13:42Z","timestamp":1771661622291,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"am","delay-in-days":330,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ijcard.2023.131290","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:19:06Z","timestamp":1692670746000},"page":"131290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effectiveness and safety of reduced-dose rivaroxaban for elderly patients with non-valvular atrial fibrillation: A subanalysis of the EXPAND study"],"prefix":"10.1016","volume":"391","author":[{"given":"Wataru","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Atarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kamouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Origasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2023.131290_bb0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/2327-6924.12494","article-title":"Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation","volume":"29","author":"Oertel","year":"2017","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"10.1016\/j.ijcard.2023.131290_bb0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","article-title":"Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation","volume":"156","author":"Chan","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2023.131290_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14737167.2018.1518134","article-title":"Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review","volume":"19","author":"Briere","year":"2019","journal-title":"Exp. Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.ijcard.2023.131290_bb0020","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","article-title":"JCS 2020 Guideline focused update on antithrombotic therapy in patients with coronary artery disease","volume":"84","author":"Nakamura","year":"2020","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2023.131290_bb0025","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.hrthm.2019.01.024","volume":"16","author":"January","year":"2019","journal-title":"Heart Rhythm."},{"issue":"2021","key":"10.1016\/j.ijcard.2023.131290_bb0030","first-page":"373","article-title":"ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.131290_bb0035","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2023.131290_bb0040","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1161\/STROKEAHA.119.025623","article-title":"Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation","volume":"50","author":"Cheng","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2023.131290_bb0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11239-019-01934-6","article-title":"Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings","volume":"48","author":"Ikeda","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ijcard.2023.131290_bb0050","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1055\/s-0042-1744543","article-title":"Rivaroxaban underdose for atrial fibrillation with stable coronary disease: the AFIRE trial findings","volume":"122","author":"Arashi","year":"2022","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2023.131290_bb0055","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"GARFIELD-AF investigators, mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131290_bb0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00380-019-01487-x","article-title":"Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation","volume":"35","author":"Kitazono","year":"2020","journal-title":"Heart Vessel."},{"key":"10.1016\/j.ijcard.2023.131290_bb0065","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2023.131290_bb0070","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2023.131290_bb0075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000068743","article-title":"Atrial fibrillation is associated with severe acute ischemic stroke","volume":"22","author":"Dulli","year":"2003","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.ijcard.2023.131290_bb0080","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/europace\/euw169","article-title":"Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot study on atrial fibrillation","volume":"19","author":"Proietti","year":"2017","journal-title":"EP Europace"},{"key":"10.1016\/j.ijcard.2023.131290_bb0085","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2023.131290_bb0090","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1074248415578172","article-title":"Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies","volume":"20","author":"Perzborn","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2023.131290_bb0095","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: a method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA."},{"key":"10.1016\/j.ijcard.2023.131290_bb0100","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.291.22.2727","article-title":"A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry","volume":"291","author":"Eagle","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.ijcard.2023.131290_bb0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2018.01.141","article-title":"The EXPAND study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation","volume":"258","author":"Shimokawa","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131290_bb0110","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00380-021-01810-5","article-title":"Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: subanalysis of the EXPAND study","volume":"35","author":"Atarashi","year":"2021","journal-title":"Heart Vessel."},{"key":"10.1016\/j.ijcard.2023.131290_bb0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1620\/tjem.240.259","volume":"240","author":"Ikeda","year":"2016","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.ijcard.2023.131290_bb0120","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2023.131290_bb0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart surgery on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2023.131290_bb0130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2023.131290_bb0135","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41598-020-58665-5","article-title":"Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients","volume":"10","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2023.131290_bb0140","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131290_bb0145","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"ORBIT-AF investigators and patients, off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131290_bb0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2023.131290_bb0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131290_bb0160","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA."},{"key":"10.1016\/j.ijcard.2023.131290_bb0165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal","volume":"180","author":"Lip","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131290_bb0170","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke."},{"key":"10.1016\/j.ijcard.2023.131290_bb0175","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2023.131290_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251325","article-title":"Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS","volume":"16","author":"Ikeda","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2023.131290_bb0185","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.010476","article-title":"Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: insights from the AFIRE trial","volume":"14","author":"Kaikita","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2023.131290_bb0190","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting","volume":"69","author":"Palmerini","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131290_bb0195","article-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"Nielsen","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2023.131290_bb0200","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41598-020-58665-5","article-title":"Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients","volume":"10","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2023.131290_bb0205","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijcard.2023.131290_bb0210","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1160\/TH10-02-0097","article-title":"Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin","volume":"104","author":"Wong","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2023.131290_bb0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/rth2.12080","article-title":"The coagulation system in atherothrombosis: implications for new therapeutic strategies","volume":"2","author":"Olie","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323011695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323011695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:22:59Z","timestamp":1760786579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527323011695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":43,"alternative-id":["S0167527323011695"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131290","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of reduced-dose rivaroxaban for elderly patients with non-valvular atrial fibrillation: A subanalysis of the EXPAND study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131290"}}